Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.

Abstract

No AccessJournal of UrologyReply to Letters to the Editor23 Jun 2023Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply Ashesh B. Jani, Gregory C. Ravizzini, Benjamin A. Gartrell, Barry A. Siegel, Przemyslaw Twardowski, Daniel Saltzstein, Mark T. Fleming, Albert Chau, Phillip Davis, Brian F. Chapin, and David M. Schuster Ashesh B. JaniAshesh B. Jani Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia More articles by this author , Gregory C. RavizziniGregory C. Ravizzini Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas More articles by this author , Benjamin A. GartrellBenjamin A. Gartrell Montefiore Medical Center, Bronx, New York More articles by this author , Barry A. SiegelBarry A. Siegel Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, WashingtonUniversity School of Medicine, St Louis, Missouri More articles by this author , Przemyslaw TwardowskiPrzemyslaw Twardowski John Wayne Cancer Institute, Santa Monica, California More articles by this author , Daniel SaltzsteinDaniel Saltzstein Urology San Antonio, San Antonio, Texas More articles by this author , Mark T. FlemingMark T. Fleming Virginia Oncology Associates, US Oncology Research, Norfolk, Virginia More articles by this author , Albert ChauAlbert Chau Blue Earth Diagnostics Ltd, Oxford, UK More articles by this author , Phillip DavisPhillip Davis Blue Earth Diagnostics, Burlington, Massachusetts More articles by this author , Brian F. ChapinBrian F. Chapin Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas More articles by this author , and David M. SchusterDavid M. Schuster Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003598AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookLinked InTwitterEmail "Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply." The Journal of Urology, Publish Ahead of Print, pp. REFERENCE 1. . Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol.2023; doi: 101097JU0000000000003493. Link, Google Scholar Google Scholar Submitted June 8, 2023; accepted June 13, 2023; published 000. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ashesh B. Jani Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia More articles by this author Gregory C. Ravizzini Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas More articles by this author Benjamin A. Gartrell Montefiore Medical Center, Bronx, New York More articles by this author Barry A. Siegel Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, WashingtonUniversity School of Medicine, St Louis, Missouri More articles by this author Przemyslaw Twardowski John Wayne Cancer Institute, Santa Monica, California More articles by this author Daniel Saltzstein Urology San Antonio, San Antonio, Texas More articles by this author Mark T. Fleming Virginia Oncology Associates, US Oncology Research, Norfolk, Virginia More articles by this author Albert Chau Blue Earth Diagnostics Ltd, Oxford, UK More articles by this author Phillip Davis Blue Earth Diagnostics, Burlington, Massachusetts More articles by this author Brian F. Chapin Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas More articles by this author David M. Schuster Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia More articles by this author Expand All Submitted June 8, 2023; accepted June 13, 2023; published 000. Advertisement PDF downloadLoading ...